The present invention relates to an analytical technology developed by using the reverse phase high performance liquid chromatography (RP-HPLC) and liquid chromatography tandem mass spectrometry (LC-MS/MS). It is devised for method development and validation to identify the chemical structures and content of the impurities in raw material of TRODAT-1 (ethanethiol,2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo [3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino],[1R-(exo-exo)]-,hydrochloride).
Technetium-99m-TRODAT-1 is a diagnostic imaging agent specifically binding to dopamine transporter in the basal ganglia region of the brain. TRODAT-1 is the unlabelled precursor of 99mTc-TRODAT-1. At present, extensively using TRODAT-1 raw material for research and development are mainly focus in the laboratories such as: Hospital of the University of Pennsylvania, USA (J. Nucl. Med. 2000 April; 41 (4) 584-9), Institute of Nuclear Energy Research, Taiwan (J. Nucl. Med. 2001 March; 42 (3) 408-13), National Laboratory of Nuclear Medicine, China (Nucl. Med. Biol. 2000 January; 27 (1) 69-75), Leuven University Hospital and Katholieke Universiteit Leuven, Belgium (Eur. J. Nucl. Med. Mol. Imaging. 2004 August; 31 (8) 1119-27), University of Munich, Germany (Eur. J. Nucl. Med. 2000 October; 27 (10) 1518-24), and Institute of Syncor Corporation (J Zhejiang Univ Sci. 2005 January; 6 (1) 22-7). However, in all literatures published already, reports related to evaluation of TRODAT-1 raw material purity and impurities have not yet become available. Moreover, up to the present, no official purity assay method is specified in the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and British Pharmacopoeia (BP). Therefore, proposal of this method is the first invention in the world that has completed the validation procedures for the impurities assay of TRODAT-1 raw material.
This invention is the first report in the world to determine the impurities and to prove the existence of oligomers in TRODAT-1 raw material by LC-MS/MS, as well as an analytical technology of quantification of the impurities by RP-HPLC.
The methodologies for the determination of impurities in TRODAT-1 raw material include instrumental facilities, reagents, sample preparations, chromatographic conditions, and calculation formulae. They are elaborated respectively as below:
(1) Instrumentation and Reagents
a. The high performance liquid chromatography (HPLC) consisted of a HPLC pump, a vacuum degasser, an injector, an autosampler, a thermostated column compartment, and a variable wavelength detector (VWD) or a photo-diode array detector (DAD).
b. Liquid chromatography—tandem mass spectrometer (LC-MS/MS).
c. HPLC C-18 reversed phase column.
d. Methanol (MeOH) and trifluoroacetic acid (TFA).
(2) Preparation of Standards, Samples and Eluent:
a. Preparation of standards and samples for HPLC: All standards and samples were prepared in HPLC exclusive sample vial, by dissolving 4-5 mg of TRODAT-1 in 1 mL of HPLC grade methanol.
b. Preparation of HPLC eluent [0.1% TFA/MeOH—H2O (50:50, v/v)]: 500 mL of HPLC grade MeOH was mixed evenly with 500 mL of deionized water, 1 mL of TFA was then added.
c. Preparation of standards and samples for MS: All standards and samples were prepared in HPLC exclusive sample vial, by dissolving 4-5 mg of TRODAT-1 in 1 mL of HPLC grade methanol, and dilution of the samples with methanol to 100˜1000 times.
(3) The HPLC Conditions:
Column: C-18 reversed phase column
Eluent: 0.1% TFA/MeOH—H2O (50:50, v/v)
Flow rate: 0.5 mL/min
Column temperature: 25° C.
Wavelength of UV detection: 210 nm
(4) The Analysis Conditions of LC-MS/MS
Ion Source: Turbo ion spray
Polarity: Positive ion mode
Scan Mode: Profile scan
Scan type: Q3 MS and Product Ion, MS2
Ion scan range: 50-950
(5) Resolution of chromatogram
R=[(tR2−tR1)/(Whalf2+Whalf1)]×1.18
tR2 and tR1 are the respective retention time of the two neighboring peaks;
Whalf2 and Whalf1 are the respective half height width of the two neighboring peaks
HPLC results were shown in
aAverage retention time for n = 9
bCorrelation curves in the injection volume range of 1˜5 μL, n = 3
The product ions mass spectra (Q3 and MS2) of peak #2, peak #7, peak #8 and peak #9 all contained a large number of m/z=426-430, 248-250 ions (as shown in FIGS. 3˜4).
First of all, it indicated that the structures of these compositions were the same as that of TRODAT-1; besides, the m/z value of the peak at retention time 19 minutes was 824.6 (accounted for 4.36% of content), which was very close to 852.18, the molecular weight of the dimer of TRODAT-1. In addition, according to the precursor ion MS experiment, it was confirmed the major source of m/z 249 was 430 amu, i.e., TRODAT-1. Therefore, it is presumed that the compositions of peak #2, peak #7, peak #8, peak #9 are very likely from the derivatives of TRODAT-1 or the results from partial degradations of the oligomer (dimer or trimer) of TRODAT-1 formed in the raw material, these composed 27.16% of the total content. It is also hypothesized that dimers of the TRODAT-1 may be existed in two forms (type I and type II) in the raw material, the suggested chemical structures are depicted in
(TRODAT-1)2 Type I (abbreviated as 1-drT//Trd-1);
(TRODAT-1)2 Type II (abbreviated as Trd-1//Trd-1).
Further verification by addition of NaOH for forced degradation testing indicated that the absorption of peak #3 (TRODAT-1), peak #8 and peak #9 reduced with time increased. Peak #2 and peak #6 formed after TRODAT-1 being degraded, and were accounted for 5.57% of the total content. As to peak #1, peak #4 and peak #5, the possible compositions are still unknown, but no relation with TRODAT-1, and the total content of these 3 peaks was 2.77%.
The examples described here are the better examples to describe this present invention, an analytical method for the impurities assay of TRODAT-1 raw material. For those who have already familiar with this skill can still consult the explanation of this invention, make modification or change and get the same results. The modification and change should still be within the scope of this invention. The invention should not be interpreted as confined to the specific form and examples as displayed and described; instead it is set forth to the following claims.